Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Compensated chronic HBV Infection
No prior treatment with adefovir dipivoxil
No interferon or lamivudine treatment for three months prior to enrollment
HBeAg positive or negative
HBV DNA viral load greater than 500,000 copies per mL
ALT between 1.2 and 10 times ULN
Positive HIV, HCV, and/or HDV serology
History of renal tubular necrosis
Serum creatinine greater than 2.0 mg/dl
History of organ transplant or use of immunosuppresive drugs